Today's Earnings Calculators Terms of Service Privacy Policy Data Sources Support Mobile app Instagram

StockRay is an AI stock analysis service by Warm Tech Company.

Warm Tech Company | CEO Jinyoung Moon | Reg. 317-27-02126

13, Cheonggyesan-ro 4-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea | partner@warmtech.company

All information provided by Warm Tech Company is for reference only and does not constitute a recommendation to buy or sell any specific stock. You are solely responsible for your investment decisions.

© 2026 Warm Tech Company. All rights reserved.

Inovio Pharmaceuticals, Inc. Stock Price·Forecast · AI Analysis | StockRay

Inovio Pharmaceuticals, Inc.

INO · Healthcare · $77M

Pre-market $1.12+0.45%

2026 Q2 earnings

Price

$1.19

$1.11

Jul 1, 26Sep 29, 26

What's this stock's score right now?

See its score for free — revenue and money flow, graded on one standard.

Quarterly Financials

RevenueOperating IncomeNet Income

9/'26

Revenue$2M

6/'26 vs prev quarter

Company Health

Market Cap$77M

Cash on Hand$37M47.6% of market cap

Free Cash Flow$-39.7B-51506.9% of market cap

Among 463 Biotechnology peers

LowMedianHigh

PBR17.6x

median 2.0xROE-1542.6%

median -54.5%

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date LoomsSep 11

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRPSep 10

INOVIO to Participate in Upcoming Investor ConferencesSep 1

Inovio Pharmaceuticals Q2 Earnings Call HighlightsAug 12

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call TranscriptAug 12

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAug 12

Related Stocks

T
Telomir Pharmaceuticals, Inc. Common Stock
A
Aldeyra The
v
vTv Therapeutics Inc.
S
Sera Prognostics, Inc.
V
Verrica Pharmaceuticals Inc.
P
PMV Pharmaceuticals, Inc.
i
iBio, Inc.
O
OS Therapies Incorporated

Daily Prices

09.29$1.11-5.13%

09.28$1.17-0.85%

09.25$1.18-2.48%

09.24$1.21-3.20%

09.23$1.25-3.10%

09.22$1.29+4.03%

09.21$1.240.00%

09.18$1.24+2.48%

09.17$1.21+5.22%

09.16$1.15-0.86%

Quarterly Revenue Growth

PriorCurrent

25년 12월26년 3월

BusinessBiotechnology·inovio.com↗

“매출은 최근 4개 분기 연속 0달러라 아직 제품 판매 단계가 아니지만, 이번 분기는 INO-3107 허가 심사가 마지막 단계로 진입한 변화가 가”

In the company's words · 2026 2분기 earnings call